Literature DB >> 26881716

The Repurposing of Old Drugs or Unsuccessful Lead Compounds by in Silico Approaches: New Advances and Perspectives.

Annamaria Martorana, Ugo Perricone, Antonino Lauria1.   

Abstract

Have you a compound in your lab, which was not successful against the designed target, or a drug that is no more attractive? The drug repurposing represents the right way to reconsider them. It can be defined as the modern and rationale approach of the traditional methods adopted in drug discovery, based on the knowledge, insight and luck, alias known as serendipity. This repurposing approach can be applied both in silico and in wet. In this review we report the molecular modeling facilities that can be of huge support in the repurposing of drugs and/or unsuccessful lead compounds. In the last decades, different methods were proposed to help the scientists in drug design and in drug repurposing. The steps strongly depend on the approach applied. It could be a ligand or a structure based method, correlated to the use of specific means. These processes, starting from a compound with potential therapeutic properties and a sizeable number of toxicity passed tests, can successfully speed up the very slow development of a molecule from bench to market. Herein, we discuss the facilities available to date, classifying them by methods and types. We have reported a series of databases, ligand and structure stand-alone software, and of web-based tools, which are free accessible to scientific community. This review does not claim to be exhaustive, but can be of interest to help in drug repurposing through in silico methods, as a valuable tool for the medicinal chemistry community.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26881716     DOI: 10.2174/1568026616666160216153457

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  11 in total

Review 1.  Drug repurposing from the perspective of pharmaceutical companies.

Authors:  Y Cha; T Erez; I J Reynolds; D Kumar; J Ross; G Koytiger; R Kusko; B Zeskind; S Risso; E Kagan; S Papapetropoulos; I Grossman; D Laifenfeld
Journal:  Br J Pharmacol       Date:  2017-05-18       Impact factor: 8.739

2.  Drugs for rare disorders.

Authors:  Serge Cremers; Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2017-06-27       Impact factor: 4.335

3.  SPIDR: small-molecule peptide-influenced drug repurposing.

Authors:  Matthew D King; Thomas Long; Daniel L Pfalmer; Timothy L Andersen; Owen M McDougal
Journal:  BMC Bioinformatics       Date:  2018-04-16       Impact factor: 3.169

Review 4.  Drug targets for COVID-19 therapeutics: Ongoing global efforts.

Authors:  Ambrish Saxena
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

5.  In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.

Authors:  Annamaria Martorana; Carla Gentile; Antonino Lauria
Journal:  Viruses       Date:  2020-07-26       Impact factor: 5.048

Review 6.  High Throughput and Computational Repurposing for Neglected Diseases.

Authors:  Helen W Hernandez; Melinda Soeung; Kimberley M Zorn; Norah Ashoura; Melina Mottin; Carolina Horta Andrade; Conor R Caffrey; Jair Lage de Siqueira-Neto; Sean Ekins
Journal:  Pharm Res       Date:  2018-12-17       Impact factor: 4.200

Review 7.  Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work.

Authors:  Rajesh Kumar; Seetha Harilal; Sheeba Varghese Gupta; Jobin Jose; Della Grace Thomas Parambi; Md Sahab Uddin; Muhammad Ajmal Shah; Bijo Mathew
Journal:  Eur J Med Chem       Date:  2019-08-08       Impact factor: 6.514

Review 8.  Drug Repurposing Strategy (DRS): Emerging Approach to Identify Potential Therapeutics for Treatment of Novel Coronavirus Infection.

Authors:  Biswa Mohan Sahoo; B V V Ravi Kumar; J Sruti; Manoj Kumar Mahapatra; Bimal K Banik; Preetismita Borah
Journal:  Front Mol Biosci       Date:  2021-02-26

9.  Off-Target-Based Design of Selective HIV-1 PROTEASE Inhibitors.

Authors:  Gabriele La Monica; Antonino Lauria; Alessia Bono; Annamaria Martorana
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

10.  Disulfiram as a novel inactivator of Giardia lamblia triosephosphate isomerase with antigiardial potential.

Authors:  Adriana Castillo-Villanueva; Yadira Rufino-González; Sara-Teresa Méndez; Angélica Torres-Arroyo; Martha Ponce-Macotela; Mario Noé Martínez-Gordillo; Horacio Reyes-Vivas; Jesús Oria-Hernández
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2017-12-01       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.